LX6171
- Generic Name
- LX6171
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- 61CSC3D89K
- Background
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
- Indication
Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizophrenia and schizoaffective disorders.
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
Phase 2
Completed
- Conditions
- Age-Related Memory Disorders
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2010-03-03
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT00691808
- Locations
- 🇳🇱
Pharmaceutical Research Associates Group BV, Zuidlaren, Netherlands
🇳🇱Kendle Netherlands, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath